logo Hematology/Oncology Research Studies: Open for Enrollment Date: 01/26/21

Category: ONCOLOGY

LEAHRN (Late Effects After High-Risk Neuroblastoma) Study

NCT#/Phase: NCT03057626
N/A
IRB#: 2017-077
Description: Potentially eligible patients identified from ANBL00B1 will be recruited by their treating COG institution to participate in one day of clinical testing. In addition to clinical and laboratory assessments, participants will provide a blood sample and patients and parents will complete self-report quality of life and psychosocial assessments. Understanding the burden of chronic disease in survivors of high-risk neuroblastoma is critical for informing appropriate long-term care of survivors as well as for planning future trials of upfront neuroblastoma therapy
Inclusion: This study will identify a large cohort of patients with high-risk neuroblastoma, all enrolled on the COG Neuroblastoma Biology study (ANBL00B1), who have survived relapse free for at least 5 years following diagnosis.
Enrollment Status: Open for enrollment
Sponsor: COG
Principal Investigator(s): Carla Golden, MD
Contact(s): Sheila Contapay-Tabilin, BSN, RN (510-428-3885 x 2611)
COG CRA Office (510-428-3885 x8334)
Study Link: https://clinicaltrials.gov/ct2/show/NCT03057626

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000